Q4 saw strong EBITDA growth and improved profitability, driven by an updated Zimmer Biomet agreement and cost reductions, despite lower full-year revenues from currency effects and discontinued business. Strategic partnerships expanded, and new therapeutic areas showed early promise.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.